It is possible that SGLT2 therapy may prove an effective means of reducing the risk of pancreatic cancer, thereby offering a potential avenue for the future reduction in pancreatic cancer incidence in patients with T2D. This evidence concerns the gene SLC5A2 and familial pancreatic carcinoma.